AbbVie Inc. buy Cantor Fitzgerald
Start price
17.05.24
/
50%
€151.82
Target price
17.05.25
€184.40
Performance (%)
-2.42%
Price
31.05.24
€148.14
Summary
This prediction is currently active. With a performance of -2.42%, the BUY prediction by Cantor_Fitzgerald is trending in the wrong direction. This prediction currently runs until 17.05.25. The prediction end date can be changed by Cantor_Fitzgerald at any time. Cantor_Fitzgerald has 50% into this predictionAbbVie (ABBV) is a multinational biopharmaceutical company based in North Chicago, Illinois. It was spun off as a separate entity from Abbott Laboratories in 2013 and is primarily focused on the development and commercialization of drugs for the treatment of conditions such as immunology, oncology, and neuroscience. Its key product is Humira, which is used to treat a range of autoimmune diseases, generating a significant portion of the company's revenue. The company also has a pipeline of promising products in various stages of development, making it a reputable player in the pharmaceutical industry.
Performance without dividends (%)
| Name | 1w |
|---|---|
| AbbVie Inc. | 2.321% |
| iShares Core DAX® | -0.552% |
| iShares Nasdaq 100 | -1.415% |
| iShares Nikkei 225® | -0.877% |
| iShares S&P 500 | -0.415% |
Comments by Cantor_Fitzgerald for this prediction
In the thread AbbVie Inc. diskutieren
AbbVie Inc. (NYSE: ABBV) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $200.00 price target on the stock.
Ratings data for ABBV provided by MarketBeat